WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407929
Description: ZEN-2759 is BRD4(BD1) inhibitor.
MedKoo Cat#: 407929
Chemical Formula: C17H16N2O2
Exact Mass: 280.1212
Molecular Weight: 280.327
Elemental Analysis: C, 72.84; H, 5.75; N, 9.99; O, 11.41
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ZEN-2759; ZEN 2759; ZEN2759;
IUPAC/Chemical Name: 1-benzyl-5-(3,5-dimethylisoxazol-4-yl)pyridin-2(1H)-one
InChi Key: CIJOVPIWGFQZFF-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H16N2O2/c1-12-17(13(2)21-18-12)15-8-9-16(20)19(11-15)10-14-6-4-3-5-7-14/h3-9,11H,10H2,1-2H3
SMILES Code: O=C(C=CC(C1=C(C)ON=C1C)=C2)N2CC3=CC=CC=C3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 280.327 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine
Olesya A. Kharenko, Reena G. Patel, S. David Brown, Cyrus Calosing, Andre White, Damodharan Lakshminarasimhan, Robert K. Suto, Bryan C. Duffy, Douglas B. Kitchen, Kevin G. McLure, Henrik C. Hansen, Edward H. van der Horst, and Peter R. Young
Publication Date (Web): August 30, 2018 (Article)
BET proteins are key epigenetic regulators that regulate transcription
through binding to acetylated lysine (AcLys) residues of histones and transcription
factors through bromodomains (BDs). The disruption of this interaction with small
molecule bromodomain inhibitors is a promising approach to treat various diseases
including cancer, autoimmune and cardiovascular diseases. Covalent inhibitors can
potentially offer a more durable target inhibition leading to improved in vivo